Barclays analyst Tim Long maintains NetApp (NASDAQ:NTAP) with a Equal-Weight and raises the price target from $74 to $85.
Atea Pharmaceuticals Announces Interim Results From Phase 2 Study Of AT-527 Showing ‘Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting’
Phase 2 Interim Virology Results Indicate Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting
AT-527 is Being Studied in Multiple Clinical Studies, Including
